Britain rejects arthritis drug

Published: Oct. 27, 2007 at 12:24 AM

LONDON, Oct. 27 (UPI) -- Britain's National Health Service has rejected the drug abatacept for severe arthritis sufferers because the cost is too high.

The National Institute for Clinical Effectiveness said the drug, marketed under the name Orencia, is effective but its price -- more than $19,000 per person per year -- is too expensive, The Independent said Friday.

Britain's National Rheumatoid Arthritis Society said 3,500 patients would qualify for the treatment.

"Whatever the price, we are talking about so few people who will now have nowhere else to go except back on to treatments which have already failed," said NRAS director Lynn Love.

© 2007 United Press International, Inc. All Rights Reserved.
Order reprints



Additional News Stories
Littell wins 'bad sex' literary award (6 min)
South Korea's Nov. exports up 18.8 percent
Alcohol: A holiday hazard for teens
NFL: New Orleans 38, New England 17
World AIDS Day: AIDS faces funding drop
NBA: Utah 102, Memphis 93
NBA: Dallas 104, Philadelphia 102
fark
If an Amtrak train leaving Boston with 48 passengers going 60 miles per hour is due to arrive in...
Time again for gold coins to start showing up mysteriously in Salvation Army kettles. Yup, there's...
Not News: Woman leaves message telling her daughter she will miss a mortgage payment, to send her...
"Teen stabbed in Anaconda." Ouch
For the last time, people - if you're going to rob the Wendy's drive-thru, make sure your mom isn't...
Palo Alto parents stand by railroad tracks all day to prevent suicidal teens from jumping in front...